Ruti Aga's Six-Year Ban: How a Forged Prescription Ended an Olympic Cycle

When the Athletics Integrity Unit (AIU) testing officer arrived for a sample after a half marathon in China in March, Ruti Aga had two paths. The first: the genuine documentation of treatment for a knee injury, with a dated steroid injection, route of administration and dosage, signed by a registered physician. The second — the path she actually chose: a prescription written by a family member, bearing the name of a clinic that did not exist. In AIU's investigation, that prescription failed three independent verification checks. And it was this document — not the methylprednisolone injection — that took the 32-year-old Ethiopian marathoner to a six-year ban and, functionally, to the end of her career.

For the winner of the 2026 Tokyo Marathon and a three-time World Marathon Majors runner-up, the case is a lesson in what I have been watching repeatedly across distance-running reporting for the past several years: documents are more fatal than substances. An athlete who could have demonstrated that her treatment was legitimate put herself in a position where nothing credible remained to demonstrate anything at all.

---

The substance identity: the technical error that changes the whole story

Most of the reports you will read labelled methylprednisolone a "prohibited steroid" and framed the ban as a steroid case. That is wrong, and the error is not merely semantic — it changes the legal foundation of the entire case.

Methylprednisolone is a glucocorticoid, falling under Class S9 of the WADA Prohibited List — not an anabolic steroid (S1). S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A legitimate therapeutic knee injection given out-of-competition is entirely legal.

The direct implication is that Aga had a fully legitimate defence pathway available — proving the interval between the treatment date and the competition. With a credentialed team physician, genuine medical records and correct timing, this case could have ended in a reprimand or a substantially reduced period. But when you fabricate a prescription, you destroy the one defence that could have worked.

Three verification failures: - The clinic did not exist — checks on the name on the prescription found no registered medical facility. - The "doctor" was not registered — the person who wrote the prescription was a family member with no medical registration. - The "old prescription pad" excuse was disowned by the clinic itself — the investigation found the claimed pad did not belong to that clinic at all.

Three failures, at three different levels. Had any one of them held up under verification, the four-year tampering charge would not have stood.

---

The six-year arithmetic: 2 + 4 = the end of a career

Understanding the structure of the AIU sanction is the most important part of this case, because it tells us what the panel thought.

The arithmetic is straightforward: 2 years for presence + 4 years for tampering = 6 years.

• The 2-year ban is for the presence of methylprednisolone — the standard sanction when a panel does not find that the athlete took the substance with intent to enhance performance. For an S9 substance, a successful therapeutic-use claim could have reduced the ban to zero or very little.
• The 4-year ban is for tampering — the standard WADA Code sanction for providing false information or altering documents. This is the part that separates the case from ordinary doping matters.

This arithmetic tells us the panel did not accept a no-significant-fault mitigation. Why? Because the tampering fact demonstrates the athlete knew there was something to hide. When you fabricate a prescription, you are yourself admitting that the real prescription was not in your possession — and that becomes decisive evidence for the panel.

Counting the ban from 10 September, and attaching the provisional suspension to the same date — both are technically the same event. This is not a relief; it is merely a paper adjustment.

At 32, a six-year ban means returning at 38. Given the depth of Ethiopian women's marathoning — where even a 2:18 performer is not automatically selected for the national team — the door to national selection is functionally closed to a 38-year-old with a doping record. The ban is six years on paper; in reality it is a career-ending decision.

---

From knee injury to forged prescription: the pipeline nobody watches

If you view this case as merely an individual mistake, you miss the core story.

In Ethiopian and Kenyan women's marathoning, chronic knee and ankle problems are an inherent part of high-volume training. A marathoner running 180–200 kilometres a week imposes a load-bearing limit on the knee joint. When that limit is crossed, inflammation follows, and the most accessible, cheapest and fastest tool for treating that inflammation is a corticosteroid injection.

Medically, this is entirely appropriate. Intra-articular methylprednisolone for knee synovitis is standard sports-medicine practice. But the problem is not that treatment happened — the problem is that there was no credible documentation of it.

When an athlete has no registered team doctor, no mechanism to obtain a TUE (Therapeutic Use Exemption), and no capacity to plan the timing between treatment need and competition — she naturally depends on the people physically near her: at her training camp, in her village, in her immediate circle. In Aga's case, that person turned out to be a family member.

This is a story of systemic vacuum more than individual corruption. When an athlete lacks access to legitimate medical support, she takes help from those around her. And when that help has to become paperwork, no trained professional remains.

It is important to note that the AIU has the authority to investigate through document verification, but it cannot tell an athlete this in advance. The prescription surfaces only when the athlete sits down to respond. And that moment determines whether the case succeeds or fails.

---

China's half marathon circuit: where money and surveillance collide

One aspect missing from most reporting is the competition where this was caught. A half marathon in China in March — which Aga won — was a Label-tier road race where China's large stakes and East Africa's elite meet.

The Label road-race circuits of China and Japan are a distinct income tier for East African marathoners. In the gaps between major marathons, these races pay good appearance fees and offer lower competitive pressure. For a 2:18–2:20-class runner, it is an attractive model.

But that same circuit has now become the AIU's most fertile testing ground. The economic and surveillance systems are colliding in the same race. The appearance-fee market and the testing apparatus both depend on the same event, and Aga became the clearest example of that collision.

The case does not really question the post-2026 strategy — it shows the consequence of that strategy. The athlete chose a mix of selective major-marathon participation and Asian label-race appearances. That was not a wrong decision — it was the practical use of resources available to a runner of her level. But when the knee problem surfaced at the same time, the most accessible quick fix was the injection.

---

The uncomfortable ratio: six years for a glucocorticoid?

Now we come to the most uncomfortable part of this piece, and I will say it plainly because I do not fear the question of double standards in case reporting.

A six-year ban for a substance with no proven endurance benefit is, in proportionality terms, a matter for serious discussion.

The facts should be clear here: - Methylprednisolone reduces inflammation and pain. It does not immediately increase running capacity, nor does it build muscle. It is a therapeutic substance with legitimate use in sport. - The four-year tampering ban is a separate matter, and it is legally appropriate. Fabricating documents is a serious offence, whatever the underlying substance.

The question is whether this ban is applied with the same rigour when the athlete is Western. And whether a four-year tampering ban, as the punishment for a forged prescription, produces the same outcome for a poor athlete as for a resource-rich one.

The AIU deserves credit for prioritising document verification. Checking documents is a system that does not care about resources — a prescription is either real or it is not. That is consistent with the principle of fairness.

But the impact of a sanction does not fall equally. A resource-rich athlete has lawyers who can contest a tampering charge, raise procedural errors and question interview conditions. A 32-year-old Ethiopian marathoner with a limited management structure has whatever she says in an interview recorded against her, with no way to withdraw it later.

Had she had proper legal representation, she might have been able to negotiate on the tampering charge or reduce those four years. Her six-year ban is not solely her own mistake — it is also the result of the inequality created by her lack of resources.

This does not mean Aga should be absolved of responsibility. Fabricating a prescription was a serious error, and its impact should not be minimised. But when we discuss the system as a whole, we must also acknowledge the inequality this ban reflects.

---

The 2026 Tokyo title: what survives and what is erased

An important technical question: will the 2026 Tokyo Marathon title and the three World Marathon Majors runner-up finishes stand?

The text does not state this explicitly, but the rules are clear. Results tied to the March race — that race's title and prize money — will almost certainly be annulled. AIU standard practice is that the result of the competition where the sample was collected is automatically disqualified. But the 2026 Tokyo title and other major results precede that date and, absent evidence of earlier use, generally remain.

But a career's value is not measured only in titles. Aga's record is that of a genuinely elite marathoner — a 2026 Tokyo win, three major runner-up finishes. Yet after this ban, her commercial standing has taken a major hit.

Sponsorship in distance running is already thin. Add a document-based doping case and brands and sponsors withdraw. Tokyo 2026 and a six-year ban are not two separate things in one career — they are two parts of one athlete's story, and the two cannot be viewed in isolation.

---

What comes next: three lessons from this case

The first lesson — medical support is no longer a luxury but basic infrastructure. In Aga's case, the forged prescription arose from a lack of accessible medical support. Had she had a registered team doctor treating her with proper documentation, the case would never have existed. The AIU must now focus not only on investigation and sanction but also on ensuring athletes have access to legitimate therapeutic support. The most effective way to reduce tampering cases is to remove the path on which an athlete feels the need for fake paperwork.

The second lesson — document verification is now anti-doping's most effective weapon. The day of the sanction made clear that the testing system checks not only the sample but also the story behind it. Aga's case is proof that when you fabricate a prescription, you break not only the law but also your only line of defence. This is both the AIU's greatest success and its greatest challenge. Success because the investigative system reaches the paperwork; challenge because athletes unable to document to that standard may become victims of injustice.

The third lesson — a six-year ban at 32 is the end of an entire career, and that is the harshest form of sanction. What we have seen in this case is an athlete who, through her own error, put herself in a position where no path to repair remained. But the purpose of a sanction should be both justice and rehabilitation. This ban may be consistent with the principle of justice, but does it leave room for rehabilitation for an athlete who could learn from the error?

If one question arises from this story, it is this: are we also examining the document that is part of the medical process of rehabilitation after sanction. Aga's case teaches us that until medical support and rehabilitation architecture are documented as carefully as we are careful during sample collection.